Pancreatic cancer stem cells: Fact or fiction?

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 4, 2009, Pages 248-259

  Bhagwandin, Vikash J ^a   Shay, Jerry W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cancer stem cell model; EMT; Gemcitabine; Label retaining cell; Metastasis; Multidrug resistance; Pancreatic cancer; Side population; Stem cell; Telomerase

Indexed keywords

TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER;

CANCER MODEL; CANCER RESEARCH; CANCER RESISTANCE; CANCER STEM CELL; CELL LABELING; CELL SUBPOPULATION; CLONOGENESIS; HUMAN; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIGENS, DIFFERENTIATION; ATP-BINDING CASSETTE TRANSPORTERS; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; TELOMERASE;

EID: 64249110064     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.02.007     Document Type: Review

References (107)

1. Dean M., Fojo T., and Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5 (2005) 275-284
2. Pardal R., Clarke M.F., and Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3 (2003) 895-902
3. J. Cohnheim, (1867).
4. Boveri T.H. Frage der Entstehung maligner Tumoren. Jena: Gustav Fischer (1914)
5. Winge O. Zytologische Untersuchungen uber die Natur maligner Tumoren II. Teerkarzinome bei Mausen. Ztschr. Zellforsch. u. mikroskop. Anat. 10 (1930) 683-735
6. Koch F.E. Zur der Metastazenbildung bei Impftumoren. Z. Krebsforsch 48 (1939) 495
7. Klein G. Use of the Ehrlich ascites tumor of mice for quantitative studies on the growth and biochemistry of neoplastic cells. Cancer 3 (1950) 1052-1061
8. Klein G. Conversion of solid into ascites tumours. Nature 171 (1953) 398-399
9. Klein G., and Klein E. The transformation of a solid transplantable mouse carcinoma into an "ascites tumor". Cancer Res. 11 (1951) 466-469
10. Klein E., and Klein G. Differential survival of solid tumor cells after inoculation into established ascites tumors. Cancer Res. 14 (1954) 139-144
11. Klein E. Gradual transformation of solid into ascites tumors permanent difference between the original and the transformed sublines. Cancer Res. 14 (1954) 482-485
12. Klein G., and Revesz L. Quantitative studies on the multiplication of neoplastic cells in vivo. I. Growth curves of the Ehrlich and MC1M ascites tumors. J. Natl. Cancer Inst. 14 (1953) 229-277
13. Hauschka T.S. The chromosomes in ontogeny and oncogeny. Cancer Res. 21 (1961) 957-974
14. Foulds L. The natural history of cancer. J. Chronic. Dis. 8 (1958) 2-37
15. Walpole A.L. Initiation and promotion in carcinogenesis. Ciba Found. Symp. Carcinogenesis (1959) 41-50
16. Makino S. Further evidence favoring the concept of the stem cell in ascites tumors of rats. Ann. N. Y. Acad. Sci. 63 (1956) 818-830
17. Levan A. Chromosome studies on some human tumors and tissues of normal origin, grown in vivo and in vitro at the Sloan-Kettering Institute. Cancer 9 (1956) 648-663
18. Levan A. Chromosomes in cancer tissue. Ann. N. Y. Acad. Sci. 63 (1956) 774-792
19. Levan A., and Hauschka T.S. Endomitotic reduplication mechanisms in ascites tumors of the mouse. J. Natl. Cancer Inst. 14 (1953) 1-43
20. Hauschka T.S., and Levan A. Cytologic and functional characterization of single cell clones isolated from the Krebs-2 and Ehrlich ascites tumors. J. Natl. Cancer Inst. 21 (1958) 77-135
21. Hauschka T.S. Correlation of chromosomal and physiologic changes in tumors. J. Cell Phys., Suppl. 52 (1958) 197-233
22. Schultz J. Malignancy and the genetics of the somatic cell. Ann. N. Y. Acad. Sci. 71 (1958) 994-1008
23. Makino S. The role of tumor stem-cells in regrowth of the tumor following drastic applications. Acta - Union Int. Contra Cancrum 15 Suppl 1 (1959) 196-198
24. Dunning W.F., Curtis M.R., and Maun M.E. The effect of added dietary tryptophane on the occurrence of 2-acetylaminofluorene-induced liver and bladder cancer in rats. Cancer Res. 10 (1950) 454-459
25. Novikoff A.B. A transplantable rat liver tumor induced by 4-dimethylaminoazobenzene. Cancer Res. 17 (1957) 1010-1027
26. Armstrong M.I., Gray A.E., and Ham A.W. Cultivation of 4-dimethylaminoazobenzene induced rat liver tumors in yolk sacs of chick embryos. Cancer Res. 12 (1952) 698-701
27. Morris H.P., Sidransky H., Wagner B.P., and Dyer H.M. Some characteristics of transplantable rat hepatoma No. 5123 induced by ingestion of N-(2-fluorenyl) phthalamic acid. Cancer Res. 20 (1960) 1252-1254
28. Potter V.R., Pitot H.C., Ono T., and Morris H.P. The comparative enzymology and cell origin of rat hepatomas. I. Deoxycytidylate deaminase and thymine degradation. Cancer Res. 20 (1960) 1255-1261
29. Wheeler G.P., Alexander J.A., Hill D.D., and Morris H.P. Activities of DNA nucleotidyltransferases and other enzymes in cell-free preparations from hepatomas of different growth rates. Cancer Res. 26 (1966) 2470-2480
30. Sugimura T., Ikeda K., Hirota K., Hozumi M., and Morris H.P. Chemical, enzymatic, and cytochrome assays of microsomal fraction of hepatomas with different growth rates. Cancer Res. 26 (1966) 1711-1716
31. Lea M.A., Morris H.P., and Weber G. Comparative biochemistry of hepatomas. VI. Thymidine incorporation into DNA as a measure of hepatoma growth rate. Cancer Res. 26 (1966) 465-469
32. Morris H.P. Studies on the development, biochemistry, and biology of experimental hepatomas. Adv. Cancer Res. 9 (1965) 227-302
33. Morris H.P., and Wagner B.P. The development of "MINIMAL DEVIATION" hepatomas. Acta - Union Int. Contra Cancrum 20 (1964) 1364-1366
34. Morris H.P., Dyer H.M., Wagner B.P., Miyaji H., and Rechcigl M. Some aspects of the development, biology and biochemistry of rat hepatomas of different growth rate. Adv. Enzyme Regul. 2 (1964) 321-333
35. Dyer H.M., Gullino P.M., and Morris H.P. Tryptophan pyrrolase activity in transplanted "MINIMAL-DEVIATION" hepatomas. Cancer Res. 24 (1964) 97-104
36. Potter V.R. Transplantable animal cancer, the primary standard. Cancer Res. 21 (1961) 1331-1333
37. Nowell P.C. The clonal evolution of tumor cell populations. Science 194 (1976) 23-28
38. Fidler I.J. Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2′-deoxyuridine. J. Natl. Cancer Inst. 45 (1970) 773-782
39. Fidler I.J. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35 (1975) 218-224
40. Fidler I.J. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis. Eur. J. Cancer 9 (1973) 223-227
41. Fidler I.J. Selection of successive tumour lines for metastasis. Nat. New Biol. 242 (1973) 148-149
42. Fidler I.J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 38 (1978) 2651-2660
43. Fidler I.J., and Kripke M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science 197 (1977) 893-895
44. Cairns J. Mutation selection and the natural history of cancer. Nature 255 (1975) 197-200
45. Lark K.G., Consigli R.A., and Minocha H.C. Segregation of sister chromatids in mammalian cells. Science 154 (1966) 1202-1205
46. Zhang H.B., Ren C.P., Yang X.Y., Wang L., Li H., Zhao M., Yang H., and Yao K.T. Identification of label-retaining cells in nasopharyngeal epithelia and nasopharyngeal carcinoma tissues. Histochem. Cell. Biol. 127 (2007) 347-354
47. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7 (2007) 834-846
48. Tumbar T., Guasch G., Greco V., Blanpain C., Lowry W.E., Rendl M., and Fuchs E. Defining the epithelial stem cell niche in skin. Science 303 (2004) 359-363
49. Talpaz M., Estrov Z., Kantarjian H., Ku S., Foteh A., and Kurzrock R. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies. J. Clin. Invest. 94 (1994) 1383-1389
50. Goodell M.A., Brose K., Paradis G., Conner A.S., and Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183 (1996) 1797-1806
51. Krishnamurthy P., and Schuetz J.D. Role of ABCG2/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 381-410
52. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62 (1993) 385-427
53. Wulf G.G., Wang R.Y., Kuehnle I., Weidner D., Marini F., Brenner M.K., Andreeff M., and Goodell M.A. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98 (2001) 1166-1173
54. Feuring-Buske M., and Hogge D.E. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood 97 (2001) 3882-3889
55. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 (1997) 730-737
56. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., and Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63 (2003) 5821-5828
57. Stanger B.Z., Stiles B., Lauwers G.Y., Bardeesy N., Mendoza M., Wang Y., Greenwood A., Cheng K.H., McLaughlin M., Brown D., Depinho R.A., Wu H., Melton D.A., and Dor Y. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8 (2005) 185-195
58. Hezel A.F., Kimmelman A.C., Stanger B.Z., Bardeesy N., and Depinho R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20 (2006) 1218-1249
59. Apelqvist A., Li H., Sommer L., Beatus P., Anderson D.J., Honjo T., Hrabe de Angelis M., Lendahl U., and Edlund H. Notch signalling controls pancreatic cell differentiation. Nature 400 (1999) 877-881
60. Esni F., Ghosh B., Biankin A.V., Lin J.W., Albert M.A., Yu X., MacDonald R.J., Civin C.I., Real F.X., Pack M.A., Ball D.W., and Leach S.D. Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development 131 (2004) 4213-4224
61. Esni F., Stoffers D.A., Takeuchi T., and Leach S.D. Origin of exocrine pancreatic cells from nestin-positive precursors in developing mouse pancreas. Mech. Dev. 121 (2004) 15-25
62. Hald J., Hjorth J.P., German M.S., Madsen O.D., Serup P., and Jensen J. Activated Notch1 prevents differentiation of pancreatic acinar cells and attenuate endocrine development. Dev. Biol. 260 (2003) 426-437
63. Jensen J., Pedersen E.E., Galante P., Hald J., Heller R.S., Ishibashi M., Kageyama R., Guillemot F., Serup P., and Madsen O.D. Control of endodermal endocrine development by Hes-1. Nat. Genet. 24 (2000) 36-44
64. Kadesch T. Notch signaling: the demise of elegant simplicity. Curr. Opin. Genet. Dev. 14 (2004) 506-512
65. Lai E.C. Notch signaling: control of cell communication and cell fate. Development 131 (2004) 965-973
66. Murtaugh L.C., and Melton D.A. Genes, signals, and lineages in pancreas development. Annu Rev. Cell. Dev. Biol. 19 (2003) 71-89
67. Murtaugh L.C., Stanger B.Z., Kwan K.M., and Melton D.A. Notch signaling controls multiple steps of pancreatic differentiation. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14920-14925
68. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., and Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 67 (2007) 1030-1037
69. Olempska M., Eisenach P.A., Ammerpohl O., Ungefroren H., Fandrich F., and Kalthoff H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. HBPD INT 6 (2007) 92-97
70. Zhou J., Wang C.Y., Liu T., Wu B., Zhou F., Xiong J.X., Wu H.S., Tao J., Zhao G., Yang M., and Gou S.M. Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J. Gastroenterol. 14 (2008) 925-930
71. Gou S., Liu T., Wang C., Yin T., Li K., Yang M., and Zhou J. Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas 34 (2007) 429-435
72. Nowell P.C., Morris H.P., and Potter V.R. Chromosomes of "minimal deviation" hepatomas and some other transplantable rat tumors. Cancer Res. 27 (1967) 1565-1579
73. Patrawala L., Calhoun T., Schneider-Broussard R., Zhou J., Claypool K., and Tang D.G. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 65 (2005) 6207-6219
74. Nguyen H., Zhang S., and Morris M.E. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci. 92 (2003) 250-257
75. Tseng E., Kamath A., and Morris M.E. Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine. Pharm. Res. 19 (2002) 1509-1515
76. Miller D.W., Fontain M., Kolar C., and Lawson T. The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett. 107 (1996) 301-306
77. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., and Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1 (2007) 313-323
78. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., and Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133 (2008) 704-715
79. Maitra A., and Hruban R.H. Pancreatic cancer. Annu. Rev. Pathol. 3 (2008) 157-188
80. Shi X., Liu S., Kleeff J., Friess H., and Büchler M.W. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62 (2002) 354-362
81. Mercalli A., Sordi V., Formicola R., Dandrea M., Beghelli S., Scarpa A., Di Carlo V., Reni M., and Piemonti L. A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. Br. J. Cancer 96 (2007) 1358-1367
82. Kornmann M., Butzer U., Blatter J., Beger H.G., and Link K.H. Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. Eur. J. Surg. Oncol. 26 (2000) 583-587
83. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., and Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 266 (1994) 2011-2015
84. Zhu X., Kumar R., Mandal M., Sharma N., Sharma H.W., Dhingra U., Sokoloski J.A., Hsiao R., and Narayanan R. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 6091-6095
85. Flores I., Benetti R., and Blasco M.A. Telomerase regulation and stem cell behaviour. Curr. Opin. Cell. Biol. 18 (2006) 254-260
86. Gellert G.C., Dikmen Z.G., Wright W.E., Gryaznov S., and Shay J.W. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res. Treat. 96 (2006) 73-81
87. Hayakawa N., Nozawa K., Ogawa A., Kato N., Yoshida K., Akamatsu K., Tsuchiya M., Nagasaka A., and Yoshida S. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry 38 (1999) 11501-11507
88. Strahl C., and Blackburn E.H. The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena. Nucleic Acids Res. 22 (1994) 893-900
89. Strahl C., and Blackburn E.H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell Biol. 16 (1996) 53-65
90. Akiyama M., Hideshima T., Shammas M.A., Hayashi T., Hamasaki M., Tai Y.T., Richardson P., Gryaznov S., Munshi N.C., and Anderson K.C. Effects of oligonucleotide N3′→P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 63 (2003) 6187-6194
91. Herbert B.S., Gellert G.C., Hochreiter A., Pongracz K., Wright W.E., Zielinska D., Chin A.C., Harley C.B., Shay J.W., and Gryaznov S.M. Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24 (2005) 5262-5268
92. Herbert B.S., Pongracz K., Shay J.W., Gryaznov S.M., and Shea-Herbert B. Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene 21 (2002) 638-642
93. Pruzan R., Pongracz K., Gietzen K., Wallweber G., and Gryaznov S. Allosteric inhibitors of telomerase: oligonucleotide N3′→P5′ phosphoramidates. Nucleic Acids Res. 30 (2002) 559-568
94. Dikmen Z.G., Gellert G.C., Jackson S., Gryaznov S., Tressler R., Dogan P., Wright W.E., and Shay J.W. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 65 (2005) 7866-7873
95. Hebrok M., Kim S.K., and Melton D.A. Notochord repression of endodermal Sonic hedgehog permits pancreas development. Genes Dev. 12 (1998) 1705-1713
96. Ingham P.W., and McMahon A.P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15 (2001) 3059-3087
97. Hebrok M. Hedgehog signaling in pancreas development. Mech. Dev. 120 (2003) 45-57
98. Berman D.M., Karhadkar S.S., Maitra A., Montes De Oca R., Gerstenblith M.R., Briggs K., Parker A.R., Shimada Y., Eshleman J.R., Watkins D.N., and Beachy P.A. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425 (2003) 846-851
99. Pasca di Magliano M., and Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat. Rev. Cancer 3 (2003) 903-911
100. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Fernández-del Castillo C., Yajnik V., Antoniu B., McMahon M., Warshaw A.L., and Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425 (2003) 851-856
101. Miyamoto Y., Maitra A., Ghosh B., Zechner U., Argani P., Iacobuzio-Donahue C.A., Sriuranpong V., Iso T., Meszoely I.M., Wolfe M.S., Hruban R.H., Ball D.W., Schmid R.M., and Leach S.D. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3 (2003) 565-576
102. Radtke F., and Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor?. Nat. Rev. Cancer 3 (2003) 756-767
103. Curry C.L., Reed L.L., Golde T.E., Miele L., Nickoloff B.J., and Foreman K.E. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 24 (2005) 6333-6344
104. van Es J.H., and Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol. Med. 11 (2005) 496-502
105. van Es J.H., van Gijn M.E., Riccio O., van den Born M., Vooijs M., Begthel H., Cozijnsen M., Robine S., Winton D.J., Radtke F., and Clevers H. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435 (2005) 959-963
106. Taipale J., Chen J.K., Cooper M.K., Wang B., Mann R.K., Milenkovic L., Scott M.P., and Beachy P.A. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406 (2000) 1005-1009
107. Nicolson G.L., Brunson K.W., and Fidler I.J. Specificity of arrest, survival, and growth of selected metastatic variant cell lines. Cancer Res. 38 (1978) 4105-4111